7Baggers
 eu approves tablet for treating postpartum depression  medwatch.com Thu, 18 Sep 2025 13:34:08 GMT
 published on: 2025-09-08 15:36:12  beatles.ru Mon, 08 Sep 2025 12:38:37 GMT
 published on: 2025-09-04 05:13:56  Newser Thu, 04 Sep 2025 10:13:56 GMT
 published on: 2025-08-31 14:19:53  Newser Sun, 31 Aug 2025 19:19:53 GMT
 published on: 2025-08-28 22:32:33  Newser Fri, 29 Aug 2025 03:32:33 GMT
 published on: 2025-08-28 14:19:46  Newser Thu, 28 Aug 2025 19:19:46 GMT
 published on: 2025-08-21 00:14:22  더경남뉴스 Wed, 20 Aug 2025 15:11:23 GMT
 why are supernus pharmaceuticals (supn) shares soaring today  FinancialContent Wed, 06 Aug 2025 17:20:00 GMT
 layoff tracker: moderna cutting 10% of workforce globally  BioSpace Fri, 01 Aug 2025 21:35:30 GMT
 Supernus strengthens neuropsychiatric portfolio with Sage Therapeutics  Pharmaceutical Technology Fri, 01 Aug 2025 07:00:00 GMT
 sage (sage) q2 revenue jumps 264%  The Globe and Mail Fri, 01 Aug 2025 07:00:00 GMT
 novo nordisk nominates ceo successor—chutes & ladders  Fierce Biotech Fri, 01 Aug 2025 07:00:00 GMT
 Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics  GlobeNewswire Thu, 31 Jul 2025 07:00:00 GMT
 SAGE Therapeutics Announces Nasdaq Delisting After Merger  TipRanks Thu, 31 Jul 2025 07:00:00 GMT

Sage Therapeutics, Inc
(NASDAQ:SAGE) 

SAGE stock logo

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product p...

Founded: 2010
Full Time Employees: 675
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends